



Presentation to ASX Small and Mid-Cap Conference

Sydney, 13 September 2021: Nyrada Inc (ASX: NYR) is pleased to provide to shareholders and the market generally the corporate presentation that will be used by Nyrada CEO, James Bonnar at the ASX Small and Mid-Cap Conference on Tuesday 14 September, at 11.00am (AEST).

Mr Bonnar will provide an update on Nyrada's Cholesterol-Lowering and Brain Injury drug development programs, as well as the vision, strategy, and market opportunity.

To register for the conference, please use the following link:

<https://www2.asx.com.au/investors/investment-tools-and-resources/events/smld>

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.

Investor & Corporate Enquiries:

Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com



Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.



ASX SMALL & MID-CAP CONFERENCE

James Bonnar
Nyrada CEO

14 September 2021

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.



Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Vision & Strategy

- 📌 To improve lives and offer hope through innovation
- 📌 We aim to deliver **novel treatments** for diseases where:
 - 📌 There is an **unmet clinical need**; or
 - 📌 Current treatments are **suboptimal**
- 📌 Commercialise early

Drug Development

Two lead programs:

Cholesterol-Lowering Program

Oral *PCSK9 inhibitor* to be used alone, or in combination with a statin

- Key value inflection point end of Phase I

Brain Injury Program

Intravenous and *intranasal* drug to help people who sustain a traumatic brain injury (TBI) or suffer a stroke

- Key value inflection point at end of Phase II

Innovative Treatments

Best-in-Class / First-Line

Clinical Need

Strong Patent Protection

Market Potential

Commercialise Early

Cholesterol-Lowering Program Overview



Cholesterol-Lowering Animation

Nyrada's Unique Solution



Oral
PCSK9
treatment



Convenient
for patient



Cost-
effective



Small molecule PCSK9 inhibitor
overcomes longstanding challenge of
oral treatment

Can be combined with statin
to deliver a first ever
single pill PCSK9/statin treatment

Program Results

Impressive Cholesterol Lowering Performance¹

- ❑ NYX-PCSK9i reduced cholesterol by almost half vs. Lipitor[®] alone (27%)
- ❑ Reduced cholesterol by 65% when dosed with Lipitor[®]
- ❑ Equivalent cholesterol reduction to injectable PCSK9 inhibitor Praluent[®]
- ❑ Well-tolerated, no adverse effects


Strong Patent Position

- ❑ US patent granted for Nyrada's PCSK9 inhibitor technology
- ❑ Development of 2nd generation compounds well advanced

¹ *In vivo* studies were conducted using a specialised mouse model, APOE*3-Leiden.CETP, specifically generated to possess human-like characteristics concerning cholesterol metabolism and cardiovascular health. The model has been used for over 170 drug intervention studies by the pharmaceutical industry over the last 15 years.


NYX-PCSK9i and Lipitor[®] Reduces Cholesterol in Mouse Model

In vivo study – June 2021




Time (days)	% Difference in plasma cholesterol versus vehicle control (<i>p</i> -value)				
	7	14	21	28	35
NYX-PCSK9i	-18% (0.066)	-24% (0.002)	-31% (0.001)	-37% (<0.001)	-46% (<0.001)
Lipitor	-13% (0.275)	-15% (0.077)	-31% (0.001)	-31% (<0.001)	-27% (<0.001)
NYX-PCSK9i + Lipitor	-33% (<0.001)	-49% (<0.001)	-56% (<0.001)	-57% (<0.001)	-65% (<0.001)

Table 1. Percentage change in total cholesterol when compared to vehicle control. There were 8 mice in each experimental group. *P*-values are shown in brackets, with significant *p*-values in bold.



Brain Injury Program Overview




Brain Injury Solution Animation

Brain Injury Problem

- 2.8 million traumatic brain injuries (TBI) in US (2017)¹
- 4.1 million TBIs globally (2020)²
- ~800,000 strokes annually in US³


- Treatment options limited to neurosurgery and supportive care
- One drug class for stroke (Suitable for less than 15% of patients)
- No FDA approved TBI drug

- High mortality
- Severe life-long disability
- High ongoing healthcare cost




Minutes

Initial injury size



Hours



Days

Final injury size


¹ *Traumatic Brain Injury-Related Deaths by Race/Ethnicity, Sex, Intent, and Mechanism of Injury – United States, 2000–2017*, Nov 22, 2019, US CDC, Jill Daugherty, PhD¹; Dana Waltzman, PhD; Kelly Sarmiento, MPH; Likang Xu, MD: <https://www.cdc.gov/mmwr/volumes/68/wr/mm6846a2.htm>

² Total TBIs in US, Germany, France, Italy, Spain, UK and Japan, Traumatic Brain Injury, Market Insight, Epidemiology and Market Forecast, DelveInsight, published January 2021.

³ US Centers for Disease Control and Prevention: <https://www.cdc.gov/stroke/index.htm>

Nyrada Brain Injury Solution

- 📌 Treatment for secondary brain injury following Stroke or TBI
 - Prevent cell death
 - Attenuate damaged brain volume
 - Improve survivability, limit disability, improve quality of life



Program Results

Proof of Concept

- ❑ NYX-1010 showed excellent potency and blood-brain barrier penetration to reach areas of the brain damaged after TBI¹

Optimised Compound

- ❑ NYR-BI01 more potent and drug-like compound than its predecessor NYX-1010¹

International Collaboration

- ❑ Collaboration secured with the world-leading scientific teams at Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney
- ❑ Strategic alignment: TBI occurs in 1 in 25 military service members
- ❑ NYR-BI01 selected for efficacy studies to be run at WRAIR

¹ Preclinical pharmacokinetic studies in an animal model announced 15 July 2020 and 15 June 2021, respectively.

Market Opportunity

- 📌 No FDA-approved treatment for TBI is currently available
- 📌 In the US, UK, Europe and Japan alone, the size of the TBI market in 2020 was US\$6.7 billion¹
- 📌 Estimated to grow at a CAGR of 5.54% between 2018–2030¹



¹ Traumatic Brain Injury, Market Insight, Epidemiology and Market Forecast, DelveInsight, published January 2021

Board of Directors



Mr John Moore
Non-Executive
Chairman



Dr Ian Dixon
Non-Executive
Director



Christopher Cox
Non-Executive
Director





Mr Peter Marks
Non-Executive
Director



Mr Marcus
Frampton
Non-Executive
Director



Dr Rüdiger
Weseloh
Non-Executive
Director

-  **Nyrada operates under the direction of a board of international calibre**
-  **Track record in finding and realising the value of biotech companies**

Key Metrics & News Flow

Market capitalisation
(as at 10 September 2021) \$44M

Share price
(as at 10 September 2021) \$0.28

CDIs free float 122,902,847

CDIs 24 months escrow 33,105,853

Cash at bank 30 June 2021 A\$13.8M

ASX listing January 16, 2020

CY 2021

CY 2022

Cholesterol-lowering program
to enter clinic: Mid CY 2022



Brain injury program
to enter clinic: 2H CY 2022



Further preclinical results: ongoing



Non-dilutive funding: ongoing

Discover More & Follow Us

Nyrada
inc



Brain Injury Solution Animation



Cholesterol-Lowering Animation

info@nyrada.com
www.nyrada.com



[@nyrada_inc](https://twitter.com/nyrada_inc)



[@nyrada_inc](https://www.linkedin.com/company/nyrada_inc)



ASX: NYR